|
|
|
|
Дата |
|---|
| 17.04.2026 |
| 16.04.2026 |
| 15.04.2026 |
| 14.04.2026 |
| 13.04.2026 |
| 10.04.2026 |
| 09.04.2026 |
| 08.04.2026 |
| 07.04.2026 |
| 06.04.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
5.10
|
5.31
|
5.10
|
5.10
|
5.34
|
5.23
|
|
|
31 111.07
|
162.00
|
|
4.88
|
5.14
|
5.07
|
4.92
|
5.09
|
4.98
|
|
|
33 824.17
|
160.00
|
|
4.94
|
5.17
|
4.59
|
4.59
|
5.13
|
5.09
|
|
|
128 575.20
|
303.00
|
|
4.41
|
4.77
|
4.06
|
4.045
|
4.67
|
4.64
|
|
|
82 079.67
|
289.00
|
|
3.84
|
4.25
|
4.03
|
3.955
|
4.035
|
3.98
|
|
|
34 899.18
|
213.00
|
|
3.83
|
4.02
|
3.94
|
3.88
|
3.945
|
3.94
|
|
|
55 626.98
|
127.00
|
|
3.79
|
3.89
|
3.85
|
3.85
|
3.95
|
3.90
|
|
|
11 938.24
|
137.00
|
|
3.90
|
4.28
|
4.10
|
3.94
|
4.10
|
3.94
|
|
|
87 905.52
|
259.00
|
|
3.94
|
4.25
|
4.09
|
3.98
|
4.10
|
4.045
|
|
|
25 086.78
|
168.00
|
|
3.97
|
4.18
|
4.35
|
4.08
|
4.38
|
4.1275
|
|
|
50 049.59
|
199.00
|
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation.
It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Показать все Скрыть